Top celebrities John Legend, Chrissy Teigen and Pedro Pascal join VCs in star-studded seed round for David Sinclair’s consumer longevity company.
Tally Health, the consumer longevity company co-founded by Dr David Sinclair today announced it has closed a $10 million seed funding round. The round was led by Forerunner Ventures, with additional participation by L Catterton, which incubated and initially backed the company, G9 Ventures and Second Sight Ventures.
Celebrities including John Legend, Chrissy Teigen, Pedro Pascal, Whitney Cummings and others, have also invested in the round.
Longevity.Technology: Sinclair is one of the world’s foremost experts on aging and human longevity, and through Tally Health he aims to help consumers improve healthspan and extend longevity at a cellular level. To achieve this, the company has developed the TallyAge epigenetic age test, along with personalized lifestyle recommendations and longevity supplements. With this funding, the company, which officially launched in February, will be aiming to scale up rapidly.
In a statement, Tally Health said the new capital will be used to support expanded research and development of new products, additional features, and technology integrations. Funds will also be allocated toward various technical, business and strategic development efforts as the company scales.
“We are not disclosing exactly what the new products or features will be just yet, however, we can share that we are investing in the research and development of new products where longevity science could be the most impactful for our members,” Tally Health CEO Melanie Goldey told us. “We are also seeking to make our products, recommendations, and interventions even more customized for our members.”
‘This is the way’… to longevity
With celebrities like singer John Legend, model Chrissy Teigen and actor Pedro Pascal (The Mandalorian and The Last of Us) joining the round, is longevity finally shifting from niche interest towards mainstream consciousness?
“We are thrilled to have attracted A-list celebrities to invest in our company,” Goldey told us. “Their interest and investment show that the conversation around longevity has transcended beyond the science and biotech community to become more mainstream. Everyone ages, and everyone wants to live better, longer.”
Goldey believes that the financing reflects a “significant and growing” consumer interest in healthspan and longevity.
“I am pleased to see our 270,000+ pre-launch waitlist converting as we attract new members, investors, and celebrities who believe in our mission to increase healthspan, drive impactful lifestyle changes, and extend human healthspan and longevity,” she said.
Forerunner partner joins board
With this investment, Kirsten Green, founding partner of Forerunner Ventures, joins Tally Health’s majority female board of directors.
“Longevity presents a remarkable, underserved opportunity, particularly in the context of its fundamental, universal importance — everyone ages, and increasingly savvy, health-conscious generations are highly motivated to have more agency over the process and ultimately live a more fulfilling life,” said Green. “The Tally Health team is in a category-defining position to open up access to scientific breakthroughs that not just slow aging, but can even help reverse it.”
“I am thrilled to partner with Kirsten who brings her passion for mission-oriented companies like ours, as well as deep strategic and operational knowledge, to our Board as we rapidly expand our reach, access, and product offering,” added Goldey.
In addition to Sinclair, Tally was co-founded by L Catterton partner and serial entrepreneur Whitney Casey.
“We founded Tally Health based on pure demand for more science-backed longevity innovations for consumers,” said Casey. “We are able to scale learnings from breakthrough epigenetic research with our own proprietary technologies to bring the science in-home for our members. There is a growing global consumer interest in evaluating health through the lens of longevity, and Tally Health’s continued growth will propel the AgeTech sector forward.”